head in Biological Technology

MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients

... data from a post approval study of MuGard in head and neck cancer patients undergoing radiation ... of patients undergoing radiation treatment for head and neck cancer experience some level of oral ... almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell ...

Celebrities to Gather to Support the Ninth Annual Starkey Hearing Foundation 'So the World May Hear' Awards Gala

... son David Mantle; Southern Methodist University head football coach June Jones; songwriter Paul ... Marilyn and Dr. Glen Nelson, Minnesota Vikings head coach Brad Childress, Minnesota Vikings trainer Eric Sugarman, University of Minnesota head basketball coach Tubby Smith, several Minnesota ...

Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial

... in the Phase I/II trial (REO 011), including 23 head and neck cancer patients. Of these head and neck patients, 17 patients have been treated ... trial included those with advanced or metastatic head and neck cancers that are refractory to standard ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

... inoperable, locoregionally advanced Stage III/IVa head and neck cancer conducted by Reddy BK et al ... that this trial is the first randomized study in head and neck cancer to their knowledge that ... (Stage III or IVa) squamous cell carcinoma of the head and neck (SCCHN). Stage III-IV SCCHN patients are ...

YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING

... (aka BIOMAb/TheraCIM/h-R3) in patients with head and neck cancer conducted by Biocon Limited ... with advanced (stage III or IVA) inoperable head and neck cancer (abstract # 6041)" will be presented in the head and Neck Cancer general poster session on Monday, ...

NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies

... as Chief Medical Officer, Luca Bolliger, PhD, as head of Business Development, and Olivia Maurel, PharmD, as head of Regulatory Affairs. Penelope joined from F.Hoffmann-La Roche AG where she was global head of Rheumatology and ...

Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs

... announces the appointment of Rachel Morten as head of Regulatory Affairs. Rachel has more ... Rachel has also served as Senior Director, Group head Regulatory Affairs for the international ... continues to mature." Rachel Morten, head of Regulatory Affairs, said: "Vantia has already ...

Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial

... Institute of Cancer Research. To date, fifteen head and neck cancer patients have been treated in the ... with advanced or metastatic solid tumours such as head and neck, melanoma, lung and ovarian that are ... include those with advanced or metastatic head and neck cancers that are refractory to standard ...

Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008

... and CEO of Oncolytics. "The selection of head and neck cancers was supported by interim results ... responses and 4/5 stable diseases were in head and neck disease; - Announced positive ... and carboplatin for patients with platinum-failed head & neck cancers; - Start of ...

Savara Expands Board of Directors, Appoints Three New Members

... Nevan Elam, Former head of Nektar Therapeutic's Pulmonary Business Unit, ... three new members. Nevan Elam, former head of the pulmonary business unit at Nektar ... where he served as senior vice president, head of the pulmonary business unit. In this role, he ...

Neurosurgery Journal Issues Supplement Dedicated to CyberKnife Radiosurgery Experience

... non-invasively, without the need for a head frame are highlighted in several of the papers, ... System does not require the use of a stabilizing head frame due to its continual image guidance and ... tissue and eliminates the need for invasive head or body stabilization frames. About ...

YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE

... of EGFR targeting antibody for treatment of head and neck cancer MISSISSAUGA, ON, Jan. 5 ... of more than 700 patients with cancers of the head and neck. The NCCS stated that it selected ... locally advanced squamous cell cancers of the head and neck immediately following surgery - the ...

Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance

... in numerous cancer types, including colorectal, head and neck, non-small cell lung, gastric and ... prostate, pancreatic, colorectal, liver and head and neck cancers, as well as sarcoma, with Phase ... cell lung cancer and advanced, metastatic head and neck cancer. Zyprexa continues to ...

Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors

... development positions, most recently serving as head of Global Development at Novartis Pharma AG in ... this, Dr. Shannon joined Sandoz in Switzerland as head of Drug Registration and Regulatory Affairs. He ... positions at Novartis, ultimately being named head of Global Development. Under Dr. Shannon's ...

WaferGen Announces Third Quarter 2008 Financial Results

... resulted primarily from an increase in head count resulting in greater salaries and wages, an ... expenses incurred as a result of an increased head count, including the hiring of a Vice President ... resulted primarily from an increase in head count resulting in greater salaries and wages, an ...

Oncolytics Biotech Inc. Announces 2008 Third Quarter Results

... in refractory patients with head and neck cancers. The decision was made following ... and carboplatin in patients with advanced head and neck cancers; - Initiation of a U.S. ... Company announced: - Eight of nine refractory head and neck cancer patients treated to date ...

Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting

... Affairs, "is that in nine evaluable late-stage head and neck cancer patients, eight of whom have ... (SCC) scan head & neck ... head & neck 1x10(10) 8 PR ...

Denser, more powerful computer chips possible with plasmonic lenses that 'fly'

... Berkeley professor of mechanical engineering and head of the research team behind this development. ... The researchers said the flying head design could potentially hold as many as 100,000 ... The researchers compared this flying plasmonic head to the arm and stylus of an LP turntable, with ...

CEL-SCI Takes Delivery of New Manufacturing Facility

... for first-line therapy of previously untreated head and neck cancer patients, and subsequently for ... for approval as a first line indication in head and neck cancer. To that end, the Company's ... administration of its cancer drug Multikine to head and neck cancer patients before they receive any ...

Lilly to Acquire ImClone Systems in $6.5 Billion Transaction

... in combination with radiation therapy for head and neck cancers. In 2007, worldwide sales of ... in breast, prostate, pancreatic, colon, liver and head and neck cancers, as well as sarcoma, with Phase ... EGFR expression. Squamous Cell Carcinoma of the head and Neck (SCCHN) ERBITUX, in combination with ...

Delaware Man Spearheads Brain Tumor Awareness

... get started on that, he's spearheading Get Your head in the Game(R), an awareness campaign in his home ... Kelly died from a brain tumor in 2004. Get Your head In The Game(R) features a series of head silhouettes and one of six accompanying facts, ...

Doctors in the US and Netherlands Using Fast RapidArc Radiotherapy Technology to Help Fight Cancer are Now Treating Tumors of the Head and Neck

... with RapidArc that we plan to treat all of our head and neck IMRT candidates using this technology." ... he added. When treating a tumor in the head or neck it is important to avoid the highly ... has now been used for the treatment of prostate, head and neck, lung, brain, spine, bone, ...

Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin

... and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is ... represents a promising option for patients with head and neck tumors refractory to standard ... include those with advanced or metastatic head and neck cancers that are refractory to standard ...

CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine

... agreement is initially restricted to the areas of head and neck cancer. Teva has the right, subject to ... for approval as a first line indication in head and neck cancer. To that end, the Company's ... administration of its cancer drug Multikine to head and neck cancer patients before they receive any ...

Oncolytics Biotech Inc. Announces 2008 Second Quarter Results

... combination therapy treatment in refractory head and neck cancer patients," said Dr. Brad ... Therapy (BSGT) conference in Edinburgh. Three head and neck patients evaluated at that time had ... of carcinoma of the head and neck. All three head and neck patients evaluated to date have ...

It takes nerves for flies to keep a level head

... to the neck muscles, and stabilise the fly's head and thus its line of sight. Lead researcher, ... says the pathway from visual signal to head movement is ingeniously designed: it uses ... its agility." Dr Krapp adds: "Keeping the head level and gaze steady is a fundamental task for ...

Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin

... and carboplatin in patients with advanced head and neck cancers. The principal investigator is ... include those with advanced or metastatic head and neck cancers that are refractory to standard ... to patients with advanced or metastatic head and neck cancer. About Oncolytics Biotech Inc. ...

Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board

... tumor types, including prostate, breast, ovarian, head and neck and lung cancers, to inform the ... of surgery, urology and radiation oncology, and head of the Section of Urologic Oncology at the ... the Department of Medicine; director of the head and neck oncology program; and deputy ...

Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin

... and carboplatin in patients with advanced head and neck cancers. The principal investigator is ... and durable responses in patients with advanced head and neck cancers," said Dr. Brad Thompson, ... a variety of advanced cancers, including head and neck cancers, will continue to be treated in ...

Oncolytics Biotech Inc. Announces 2008 First Quarter Results

... Gene Therapy conference in Edinburgh. Three head and neck patients evaluated to date have had ... to date have a diagnosis of carcinoma of the head and neck. All three head and neck patients evaluated to date have had ...

Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial

... in patients with advanced cancers including head and neck, melanoma, lung and ovarian. "The ... with advanced or metastatic solid tumours such as head and neck, melanoma, lung and ovarian cancers that ... 350,000 people are diagnosed annually with head & neck, melanoma, lung and ovarian cancers. ...

Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial

... to date have a diagnosis of carcinoma of the head and neck. All three head and neck patients evaluated to date have had ... REOLYSIN(R) is active. "These early results in head and neck patients are remarkable, considering the ...

Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007

... restructuring program to reduce expenses and head count -- Received CE Mark approvals for the use ... and simplify our business, including expense and head count reductions and the sale of non- strategic ... associated with the Company's expense and head count reduction initiatives; and -- $174 million ...

Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data

... in approximately 300 patients with advanced head and neck cancer. Viventia recently completed an ... (the 'TARGET' trial) in patients with advanced head and neck cancer. Proxinium(TM) has Orphan Drug ... 3 clinical trial for the treatment of head and neck cancer. Viventia is also developing ...

Amarin Provides Business Update and Announces Implementation of Reverse Stock Split

... 16 years experience Dr. Declan head of Research and SVP and head of Doogan Development ... 30 years experience Dr. Keith Wood head of Research and Pfizer, Roche, Janssen ...

New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia

... MYOBLOC to reduce the severity of abnormal head position and neck pain associated with CD -- ... dystonia to reduce the severity of abnormal head position and neck pain associated with cervical ... dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. For more ...

Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings

... studies in patients with advanced breast, head and neck, lymphoid, and non-small cell ... studies in patients with advanced breast, head and neck, lymphoid, and non-small cell lung ... studies in patients with advanced breast, head and neck, lymphoid, and non-small cell lung ...

MedImmune Announces Seven Key Promotions and New Hires

... and Ortho Biotech, including therapeutic area head for oncology and acting head of oncology research & development. Most recently he held the position of vice president, head of clinical oncology, responsible for strategic ...

Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features

... to help reduce shear and friction when the head of the bed is raised. -- Bed exit alarms ... of falls and are an industry first. -- head of Bed Angle Display lets the caregiver know if a patient's head is above or below the 30-degree point, a key ...

Nitec Pharma Expands Senior Management Team

... Stephan Witte, as Chief Medical Officer and head of Global Clinical Development, Dr. Michael ... Dr. Stephan Witte, the Chief Medical Officer and head of Global Clinical Development, has more than 10 ... Director at Madaus GmbH. Before, Dr. Rogasch was head of Production and Development at alphamed ...